Patents by Inventor Paul V. Rucker
Paul V. Rucker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140142316Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: April 16, 2013Publication date: May 22, 2014Applicant: Pfizer Inc.Inventors: Hengmiao CHENG, Xiao HU, Kevin D. JEROME, Mark G. OBUKOWICZ, Lisa Maria OLSON, Paul V. RUCKER, Ronald Keith WEBBER
-
Patent number: 8552035Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: February 27, 2012Date of Patent: October 8, 2013Assignee: Pfizer Inc.Inventor: Paul V. Rucker
-
Patent number: 8445520Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: December 21, 2011Date of Patent: May 21, 2013Assignee: Pfizer Inc.Inventors: Hengmiao Cheng, Xiao Hu, Kevin D. Jerome, Mark G. Obukowicz, Lisa Maria Olson, Paul V. Rucker, Ronald Keith Webber
-
Publication number: 20120157502Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: February 27, 2012Publication date: June 21, 2012Applicant: Pfizer Inc.Inventor: Paul V. RUCKER
-
Publication number: 20120095062Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: Pfizer Inc.Inventors: Hengmiao (Henry) CHENG, Xiao HU, Kenvin D. JEROME, Mark OBUKOWICZ, Lisa OLSON, Paul V. RUCKER, Ronald Keith WEBBER
-
Patent number: 8158660Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: May 8, 2009Date of Patent: April 17, 2012Assignee: Pfizer Inc.Inventors: Hengmiao Cheng, Xiao Hu, Kevin D. Jerome, Mark G. Obukowicz, Lisa Maria Olson, Paul V. Rucker, Ronald Keith Webber
-
Publication number: 20120088802Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: May 8, 2009Publication date: April 12, 2012Applicant: Pfizer, Inc.Inventors: Hengmiao (Henry) Cheng, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Patent number: 8148409Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: July 20, 2009Date of Patent: April 3, 2012Assignee: Pfizer Inc.Inventor: Paul V. Rucker
-
Publication number: 20100286214Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: May 8, 2009Publication date: November 11, 2010Applicant: Pfizer, Inc.Inventors: Hengmiao (Henry) Cheng, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Patent number: 7786097Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: July 21, 2009Date of Patent: August 31, 2010Assignee: Pfizer Inc.Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A Decresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Publication number: 20100069444Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: July 20, 2009Publication date: March 18, 2010Applicant: PFIZER, INC.Inventor: Paul V. Rucker
-
Patent number: 7652031Abstract: Compounds which mimic the chemical and/or biological activity of discodermolide are provided.Type: GrantFiled: August 6, 2002Date of Patent: January 26, 2010Assignee: The Trustees Of The University of PennsylvaniaInventors: Amos B Smith, III, Thomas Beauchamp, Matthew J. Lamarche, Paul V. Rucker
-
Patent number: 7629363Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: September 14, 2005Date of Patent: December 8, 2009Assignee: Pfizer IncInventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee
-
Publication number: 20090270350Abstract: This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxyge?ase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R1, R2a, R2b, R2c, R2d, R2e, R3a, R3b, R3c, R3d, R4, R5, R6, R7a, R7b, R7c, R7d and R7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.Type: ApplicationFiled: February 5, 2007Publication date: October 29, 2009Inventors: Balekudru Devadas, Susan J. Hartmann, Richard F. Heier, Kevin D. Jerome, Steve A. Kolodziej, John Mathias, Monica B. Norton, Michele A. Promo, Paul V. Rucker, Shaun Selness
-
Patent number: 7598231Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: GrantFiled: January 31, 2008Date of Patent: October 6, 2009Assignee: Pfizer, Inc.Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A DeCresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Publication number: 20090215817Abstract: This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula: wherein R1, R2, R3, R4, and R5 are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.Type: ApplicationFiled: August 8, 2005Publication date: August 27, 2009Inventors: Paul V. Rucker, Kevin D. Jerome, Shaun R. Selness, John E. Baldus, Li Xing
-
Publication number: 20090209577Abstract: This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula: wherein R1, R2 and R3, are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.Type: ApplicationFiled: August 8, 2005Publication date: August 20, 2009Applicant: PFIZER INC.Inventors: Paul V. Rucker, Kevin D. Jerome, Shaun R. Selness, John E. Baldus, Li Xing
-
Publication number: 20080312294Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: January 31, 2008Publication date: December 18, 2008Applicant: Pfizer, Inc.Inventors: Hengmiao (Henry) Cheng, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Publication number: 20080188443Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: January 31, 2008Publication date: August 7, 2008Applicant: Pfizer, Inc.Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A. DeCresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Patent number: 7067540Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: February 14, 2003Date of Patent: June 27, 2006Assignee: Pharmacia CorporationInventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee